AFP and hepatocellular carcinoma: In addition, cabozantinib is the only drug given to all HCC patients after first-line systemic treatment (e.g., sorafenib) regardless of the baseline AFP level or the tolerability of sorafenib treatment of patients, which further distinguishes cabozantinib from ramucirumab and regorafenib (14).